RxDoctor Payments DataLook up a doctor →

Mark Borchelt, MD

Endocrinology, Diabetes & Metabolism · Gulfport, MSNPI 1194776286

Payments from drug & device makers

$1,057,741in general payments, 2019–2025

Across 2,806 payments — averaging $376.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$355K
  • Eli Lilly$265K
  • Novo Nordisk$90K
  • GRT US Holding, Inc.$87K
  • Amgen$57K
  • Boehringer Ingelheim$53K
  • plus $151K from 54 others
$7,040in research payments, 2019–2025

Across 5 payments — averaging $1408.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC854$355,117
Eli Lilly37$265,249
Novo Nordisk247$89,560
GRT US Holding, Inc.155$86,517
Amgen(2 entities)163$57,304
Boehringer Ingelheim108$52,600
Averitas Pharma Inc.67$27,212
Corcept Therapeutics98$26,115
Johnson & Johnson45$20,476
AbbVie(2 entities)31$18,951
Intercept Pharmaceuticals, Inc.6$17,438
Bayer61$8,522
Clarus Therapeutics Inc.19$7,990
Abbott140$3,701
Boehringer Ingelheim International GmbH67$3,366
Medtronic(2 entities)90$3,020
Chiasma, Inc.2$1,700
AstraZeneca58$1,452
Amryt Pharma Holdings Ltd10$1,439
Xeris Pharmaceuticals, Inc.73$1,350
Dexcom, Inc.56$1,074
Sanofi-aventis U.S. LLC60$1,035
Radius Health, Inc.65$993
Merck36$620
Insulet Corporation19$522
Mannkind Corporation38$453
BETA Bionics, Inc.15$432
BD17$302
Zealand Pharma US, Inc.12$274
Tandem Diabetes Care, Inc.8$256
Valeritas, Inc.13$255
Novartis15$254
Amarin Pharma, Inc.12$249
IBSA Pharma Inc.11$215
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$206
Recordati_rare_diseases_inc.10$176
Lifescan, Inc.12$166
Regeneron Healthcare Solutions, Inc.5$166
Embecta Corp.6$116
Ascendis Pharma Endocrinology Inc4$78
Esperion Therapeutics, Inc.5$75
Vifor Pharma, Inc.6$72
Madrigal Pharmaceuticals3$69
Amneal Pharmaceuticals LLC5$64
Antares Pharma, Inc.4$63
Almatica Pharma LLC3$62
Tolmar, Inc.4$58
Ultragenyx Pharmaceutical Inc.3$56
Alfasigma USA, Inc.3$48
Acerus Pharmaceuticals Corporation2$36
Kyowa Kirin, Inc.1$26
Shire North American Group Inc2$26
Neurocrine Biosciences, Inc.1$24
Alvogen Inc1$24
Nevro Corp.1$23
Senseonics, Incorporated1$22
Sequel Med Tech, LLC1$20
Cequr Corporation1$18
Amphastar Pharmaceuticals, Inc.1$18
UCB, Inc.1$15

How this compares

$1,057,741 in reported general payments places this provider in the 95th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.

See all endocrinology, diabetes & metabolism providers in Mississippi →

Medicare billing

Part B allowed, 2024
$118,795
Medicare patients
728
Services billed
2,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Gulfport

See the full list for Mississippi →

Where these figures come from

Is this you, or does something look wrong? →